Bio-Techne
Bio-Techne Quality Analysis
Bio-Techne (TECH) is an average quality business scoring 64/100. While the company generates positive returns, it lacks the exceptional attributes that characterize durable competitive advantages. Investors should demand a meaningful discount to fair value before investing.
Bio-Techne a-t-elle un rempart concurrentiel (moat) solide ?
Bio-Techne operates with a narrow competitive moat. While the business generates acceptable returns, it lacks the consistent margin superiority or return on capital that would indicate strong pricing power or durable competitive advantages. Competition could erode profitability over time.
Bio-Techne a-t-elle un pricing power dans son secteur ?
Bio-Techne demonstrates moderate pricing power. The company maintains healthy margins and has been able to grow revenue without significant margin compression. Margins have remained relatively stable. This suggests reasonable, though not exceptional, ability to pass costs through to customers.
Quelle est la prévisibilité de l'activité de Bio-Techne ?
Bio-Techne is a highly predictable business with remarkably consistent financial performance. Revenue growth has been steady with low volatility, and the company has delivered positive free cash flow in 9 of the last 9 years. This consistency makes future earnings relatively easy to forecast with confidence.
Bio-Techne est-elle financièrement solide ?
Bio-Techne has an exceptionally strong balance sheet with low leverage. The company could comfortably weather a severe economic downturn. This financial fortress provides strategic flexibility and reduces risk for long-term shareholders.
Quelle est l'efficacité de la stratégie d'allocation de capital de Bio-Techne ?
Bio-Techne has mixed capital allocation. Returns on capital are mediocre, suggesting some investments are not generating adequate returns. Management could be more disciplined in deploying shareholder capital.
Bio-Techne a-t-elle une direction de haute qualité ?
Bio-Techne's management shows mixed results. Operational efficiency could be improved, and capital deployment decisions have been inconsistent. The team needs to demonstrate clearer focus on shareholder value creation.
Bio-Techne est-elle une entreprise de qualité ?
Bio-Techne est une entreprise de qualité an average avec un score de qualité de 64/100
Predicted probability of operating margin improvement over the next 12 months
- Predictability is the strongest dimension at 89/100.
- Capital allocation is the weakest area at 40/100 and needs attention.
- Average gross margin of 67.1% over 5 years.
- Positive free cash flow in 9 of the last 9 years.
Quelle est le prix juste de l'action Bio-Techne ?
Bio-Techne est-elle un bon investissement à $72 ?
L'analyse suivante est fournie à des fins d'information et d'éducation uniquement. Elle ne constitue pas un conseil financier, un conseil en investissement ou une recommandation d'achat ou de vente de titres. Les opinions exprimées sont basées sur des informations publiques et des données historiques. Beanvest et ses contributeurs peuvent détenir des positions dans les titres mentionnés. Les investisseurs doivent effectuer leur propre diligence raisonnable ou consulter un conseiller financier agréé avant de prendre toute décision d'investissement.